2C-D

Discovery

2C-D was first synthesized by Beng T. Ho and colleagues at the Texas Research Institute of Mental Sciences in 1970.^[4] Alexander Shulgin began self-testing the compound at sub-threshold doses as early as 1964, reaching active doses by 1974–1975.^[4] The human psychopharmacology of 2C-D was first described by Shulgin and Michael Carter in 1975, though this paper has not been located in indexed databases.

Clinical and cultural significance

Under the designation LE-25, 2C-D was explored by German psychiatrist Hanscarl Leuner as an adjunct in psycholytic psychotherapy — used to extend and modulate the effects of co-administered substances rather than as a primary agent.^[5][9] Shulgin later documented the compound as entry #23 in PiHKAL,^[5] providing a complete synthesis route, a dose range of 20–60 mg oral, and bioassay narratives describing a subtle, communication-facilitating experience with mildly psychedelic character emerging only at the upper dosage extreme.

Prohibition

2C-D remained unscheduled in the United States for over four decades following its synthesis. The Synthetic Drug Abuse Prevention Act of 2012, enacted as part of FDASIA (P.L. 112-144), explicitly placed 2C-D in Schedule I of the Controlled Substances Act.^[6] The United Kingdom had already classified it as Class A, Schedule 1 under a 2002 amendment encompassing all PiHKAL phenethylamines.^[4]

Structural class

2C-D belongs to the 2C family of substituted phenethylamines — compounds sharing a 2,5-dimethoxyphenethylamine backbone with a variable substituent at the 4-position of the aromatic ring. The "2C" designation refers to the two-carbon ethylamine side chain, distinguishing these compounds from their α-methylated amphetamine counterparts (the DOx series). 2C-D bears a 4-methyl group — the smallest commonly encountered in the 2C family — making it the structural phenethylamine counterpart of DOM.^[10]

This minimal substituent is directly responsible for 2C-D's low potency relative to more heavily substituted relatives like 2C-B (4-bromo) and 2C-I (4-iodo).^[11] In the 2C series, larger and more lipophilic 4-position groups generally confer stronger receptor binding and greater psychedelic potency.

Molecular properties

The molecule consists of a phenethylamine core with methoxy groups at the 2- and 5-positions and a methyl group at the 4-position. The two methoxy groups occupy a para-arrangement relative to each other, with the 4-methyl group positioned between them on the ring. As a primary amine with no chirality centers, 2C-D is achiral and does not exhibit stereoisomerism.

Physical properties

2C-D is most commonly encountered as the hydrochloride salt, with a reported melting point of 213–214°C.^[9] No published data on solubility, stability, or degradation pathways specific to 2C-D were identified in the literature.

Mechanism of action

2C-D produces its psychedelic effects through agonism at serotonin 5-HT₂A receptors,^[11][3] the principal molecular target for classical hallucinogenic phenethylamines and tryptamines. Activation of these receptors on neurons in the prefrontal cortex increases excitatory signaling, a mechanism believed to underlie the perceptual and cognitive changes characteristic of psychedelic states.^[2]

2C-D also acts at 5-HT₂C receptors,^[1] though the contribution of this target to its subjective effects has not been established. The compound is classified as a "weak" serotonin receptor agonist at both targets,^[1] placing it below more potent 2C-series compounds such as 2C-B, 2C-I, and 2C-E, which carry larger substituents at the 4-position.

Drug discrimination studies in rats trained to recognize LSD have confirmed that 2C-D engages the same serotonergic pathway,^[12][13] supporting a shared hallucinogenic mechanism across the class.

Pharmacokinetics

No pharmacokinetic data specific to 2C-D exist in the published literature. Bioavailability, plasma half-life, and clearance pathways have not been characterized in humans. For the 2C series broadly, metabolism is believed to proceed through removal of methoxy groups from the aromatic ring, with MAO-A serving as a primary metabolic enzyme.^[7] Some involvement of liver enzymes (CYP450 family) has been suggested for related 2C analogs but remains unconfirmed for 2C-D specifically.^[14]

Effects begin within 15–45 minutes of oral ingestion, with a total duration of 4–6 hours.^[5] These timing parameters derive from Shulgin's self-experiments rather than controlled pharmacokinetic studies.

Where it acts

2C-D's 5-HT₂A agonism engages the same cortical circuits characterized for other serotonergic psychedelics. These receptors are concentrated on neurons in the prefrontal cortex, where their activation increases excitatory signaling and disrupts the brain's normal filtering of sensory and cognitive input.^[2][3] At the network level, serotonergic psychedelics typically disrupt default mode network integrity, reduce thalamic gating, and increase the overall complexity of brain activity — though no neuroimaging studies have been conducted with 2C-D.

The compound's weak receptor binding suggests these network-level disruptions are proportionally milder than those produced by higher-potency psychedelics such as LSD or psilocybin, consistent with 2C-D's subdued phenomenological profile at standard doses.

Why it matters

The entropic brain hypothesis proposes that psychedelics increase the disorder of spontaneous brain activity, expanding the range of accessible conscious states. The related REBUS model extends this, suggesting psychedelics loosen the brain's reliance on prior expectations to allow more flexible cognition.citation needed 2C-D's characterization as "pharmacological tofu" — potentiating other substances without strongly defining the experience — may represent a partial loosening of priors insufficient to generate full psychedelic phenomenology at standard doses.

Whether 2C-D's weak 5-HT₂A agonism is sufficient to promote structural neuroplasticity — dendritic growth and new synaptic connections mediated by BDNF and related signaling — has not been investigated.citation needed

Toxicity

No lethal dose data have been established for 2C-D in any species, and no deaths or serious adverse events attributed specifically to 2C-D alone appear in the published literature.^[7] A clinical toxicology review documented at least five deaths involving 2C-series compounds overall, but these involved other members — primarily 2C-E and 2C-I — with no 2C-D-specific fatalities reported.^[7]

For the 2C series as a class, documented acute adverse presentations include^[7]:

• Hallucinations, agitation, aggression, and dysphoria
• Elevated blood pressure and rapid heart rate
• Seizures
• Dangerously elevated body temperature
• Excited delirium (documented in fatalities involving other 2C compounds)
• Serotonin toxicity

2C-D's demonstrated monoamine oxidase inhibitory potential^[8] adds an additional toxicological mechanism: inhibiting monoamine oxidase elevates brain monoamine levels, which can intensify cardiovascular stress, agitation, and serotonin toxicity — particularly in combination with other serotonergic or stimulant substances.

Psychological risks

No controlled data on psychological risk specific to 2C-D exist. Class-level risks for serotonergic psychedelics include acute psychological distress, anxiety, panic reactions, and psychological destabilization in individuals with personal or family histories of psychotic disorders.

The relatively mild profile of 2C-D at standard doses suggests lower acute psychological risk than more potent psychedelics, though the poorly documented high-dose range carries unknown risk. inferred

Tolerance and dependence

Tolerance develops rapidly after a single use of any serotonergic psychedelic. In mouse studies, tolerance to the effects of the serotonin 2A receptor agonist DOI developed within 24 hours of a single dose, with progressive tolerance over 4 days of repeated administration.^[15] This tolerance is driven by downregulation in the frontal cortex and is independent of β-arrestin-2.^[15] Cross-tolerance between DOI and LSD was confirmed in the same study, supporting the expectation that all 5-HT₂A agonist psychedelics — including 2C-D — share cross-tolerance.

No evidence of physical dependence, withdrawal, or compulsive redosing exists for 2C-D or any 2C-series compound.^[7]

Drug interactions

Tramadol is classified as a dangerous interaction. Tramadol blocks the SERT, raising synaptic serotonin.^[16] Combined with 2C-D's receptor agonism and MAO inhibition,^[8] this produces converging serotonergic stimulation. Tramadol fatalities in combination with MAOIs are documented.^[17] Tramadol also lowers the seizure threshold, compounding the seizure risk associated with 2C-series compounds.

Classical MAOIs combined with 2C-D would produce dual MAO inhibition alongside direct 5-HT₂A agonism — a high-risk combination for serotonin toxicity.^[8][17]

2C-series compounds have been documented in serotonin syndrome case reports when combined with other serotonergic agents.^[18]

Contraindications

No published contraindications specific to 2C-D exist. The following are inferred from its pharmacological class and MAO inhibitory propertiesinferred:

• Personal or family history of psychotic disorders — 5-HT₂A agonism can precipitate or worsen psychotic episodes in vulnerable individuals
• Bipolar disorder — psychedelic use carries risk of triggering manic episodes
• Heart conditions — elevated blood pressure and rapid heart rate are documented for the 2C-series class^[7] and may be clinically significant in those with pre-existing cardiovascular disease
• Concurrent MAOI use — dual MAO inhibition plus 5-HT₂A agonism creates high risk for serotonin toxicity^[8]
• Concurrent serotonergic medication — SSRIs, SNRIs, tramadol, and other serotonin-elevating agents create compounding risk
• Seizure disorders — seizures are documented among 2C-series adverse events^[7]
• Pregnancy — no reproductive toxicity data exist; standard precautionary contraindication applies

2C-D is controlled as a scheduled substance in multiple jurisdictions. In the United States, it was explicitly listed in Schedule I through the synthetic Drug Abuse Prevention Act of 2012.^[6] Prior to 2012, 2C-D was not specifically scheduled under federal law, though it may have been subject to prosecution under the Federal Analogue Act if intended for human consumption.

International scheduling varies, with most jurisdictions classifying 2C-D under blanket phenethylamine prohibitions or specific substance listings.

European Union country-by-country scheduling was not confirmed from primary legal databases during this research cycle. 2C-D is reported to be controlled across most EU member states, but specific schedules and enactment dates require verification. citation needed